Inflammation in Cystic Fibrosis-When and Why? Friend or Foe?

Caroline Elston; Duncan Geddes

doi:10.1055/s-2007-981649

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2007; 28(3): 286-294
DOI: 10.1055/s-2007-981649

Inflammation in Cystic Fibrosis-When and Why? Friend or Foe?

Caroline Elston¹ , Duncan Geddes¹

¹Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom

Abstract

ABSTRACT

Pulmonary infection and an excessive neutrophil-driven inflammatory response are responsible for most of the morbidity and mortality associated with cystic fibrosis. Although inflammation is first and foremost a protective response to injury or infection it has the potential to cause considerable harm when it is excessive. Whereas most published reports emphasize the damaging effects of the chronic inflammatory response in cystic fibrosis, the beneficial effects are more difficult to quantify. Low levels of inflammation may assist in clearing infection, particularly early in the disease process, and surges of acute inflammation may be beneficial during exacerbations. Anti-inflammatory therapies are used to modify the inflammatory response but there is clearly a need to preserve the protective aspects of the inflammatory response because host defense and a fine balance exist between benefit and harm. The underlying processes involved in the inflammatory response are reviewed along with current and future anti-inflammatory therapies.

KEYWORDS

Cystic fibrosis - inflammation - host defense

Volltext

Referenzen

REFERENCES

1 Davis P B, Drumm M, Konstan M W. Cystic fibrosis. Am J Respir Crit Care Med. 1996; 154 1229-1256
2 Chmiel J F, Berger M, Konstan M W. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 2002; 23 5-27
3 Kumar V, Cotran R S, Robbins S L. Robbins Basic Pathology. 7th ed. Philadelphia; Saunders 2003
4 Bonfield T L, Panuska J R, Konstan M W et al.. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995; 152(6 Pt 1) 2111-2118
5 Khan T Z, Wagener J S, Bost T, Martinez J, Accurso F J, Riches D W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995; 151 1075-1082
6 Konstan M W, Walenga R W, Hilliard K A, Hilliard J B. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993; 148(4 Pt 1) 896-901
7 Muhlebach M S, Stewart P W, Leigh M W, Noah T L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 1999; 160 186-191
8 Noah T L, Black H R, Cheng P W, Wood R E, Leigh M W. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis. 1997; 175 638-647
9 Barnes P J, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336 1066-1071
10 Bonfield T L, Konstan M W, Burfeind P, Panuska J R, Hilliard J B, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995; 13 257-261
11 Karp C L, Flick L M, Park K W et al.. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004; 5 388-392
12 Starosta V, Ratjen F, Rietschel E, Paul K, Griese M. Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J. 2006; 28 581-587
13 Gibson R L, Burns J L, Ramsey B W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168 918-951
14 Taggart C C, Greene C M, Carroll T P, O'Neill S J, McElvaney N G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med. 2005; 171 1070-1076
15 Sagel S D, Sontag M K, Wagener J S, Kapsner R K, Osberg I, Accurso F J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr. 2002; 141 811-817
16 Matsui H, Grubb B R, Tarran R et al.. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998; 95 1005-1015
17 Smith J J, Travis S M, Greenberg E P, Welsh M J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996; 85 229-236
18 Moraes T J, Plumb J, Martin R et al.. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Cell Mol Biol. 2006; 34 364-374
19 Pier G B. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA. 2000; 97 8822-8828
20 de Bentzmann S, Roger P, Dupuit F et al.. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun. 1996; 64 1582-1588
21 Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA. 1995; 92 3019-3023
22 Saiman L, Cacalano G, Gruenert D, Prince A. Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun. 1992; 60 2808-2814
23 Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest. 1993; 92 1875-1880
24 DiMango E, Ratner A J, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest. 1998; 101 2598-2605
25 Day B J, van Heeckeren A M, Min E, Velsor L W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary Pseudomonas infection. Infect Immun. 2004; 72 2045-2051
26 Velsor L W, van Heeckeren A, Day B J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol. 2001; 281 L31-L38
27 Tirouvanziam R, Conrad C K, Bottiglieri T, Herzenberg L A, Moss R B, Herzenberg L A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA. 2006; 103 4628-4633
28 Elphick H E, Demoncheaux E A, Ritson S, Higenbottam T W, Everard M L. Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax. 2001; 56 151-152
29 Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol. 1997; 24 173-177
30 Kelley T J, Drumm M L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest. 1998; 102 1200-1207
31 Chow C W, Landau L I, Taussig L M. Bronchial mucous glands in the newborn with cystic fibrosis. Eur J Pediatr. 1982; 139 240-243
32 Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol. 1982; 106 303-311
33 Armstrong D S, Grimwood K, Carlin J B et al.. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997; 156(4 Pt 1) 1197-1204
34 Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995; 20 63-70
35 Rosenfeld M, Gibson R L, McNamara S et al.. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001; 32 356-366
36 Tirouvanziam R, de Bentzmann S, Hubeau C et al.. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol. 2000; 23 121-127
37 Tabary O, Zahm J M, Hinnrasky J et al.. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol. 1998; 153 921-930
38 Bonfield T L, Konstan M W, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol. 1999; 104 72-78
39 Stecenko A A, King G, Torii K et al.. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation. 2001; 25 145-155
40 Aldallal N, McNaughton E E, Manzel L J et al.. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med. 2002; 166 1248-1256
41 Becker M N, Sauer M S, Muhlebach M S et al.. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med. 2004; 169 645-653
42 van Heeckeren A M, Schluchter M D, Xue W, Davis P B. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med. 2006; 173 288-296
43 Armstrong D S, Hook S M, Jamsen K M et al.. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005; 40 500-510
44 Saadane A, Soltys J, Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol. 2006; 117 1163-1169
45 Gutierrez J P, Grimwood K, Armstrong D S et al.. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J. 2001; 17 281-286
46 Meyer K C, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med. 1997; 156 1536-1540
47 Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?. Pediatr Pulmonol. 2005; 40 471-476
48 Armstrong D S, Grimwood K, Carzino R, Carlin J B, Olinsky A, Phelan P D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995; 310 1571-1572
49 Colasurdo G N, Fullmer J J, Elidemir O, Atkins C, Khan A M, Stark J M. Respiratory syncytial virus infection in a murine model of cystic fibrosis. J Med Virol. 2006; 78 651-658
50 Armstrong D, Grimwood K, Carlin J B et al.. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998; 26 371-379
51 van Ewijk B E, van der Zalm M M, Wolfs T F, van der Ent C K. Viral respiratory infections in cystic fibrosis. J Cyst Fibros. 2005; 4(Suppl 2) 31-36
52 Moss R B. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Med Mycol. 2005; 43(Suppl 1) S203-S206
53 Burns J L, Gibson R L, McNamara S et al.. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001; 183 444-452
54 Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997; 23 330-335
55 Valerius N H, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991; 338 725-726
56 Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998; 53 732-737
57 Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34 91-100
58 Nixon G M, Armstrong D S, Carzino R et al.. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001; 138 699-704
59 Wiesemann H G, Steinkamp G, Ratjen F et al.. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998; 25 88-92
60 Wood D M, Smyth A R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006; (1) , CD004197
61 Hendry J, Elborn J S, Nixon L, Shale D J, Webb A K. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa . Eur Respir J. 1999; 14 435-438
62 Liou T G, Adler F R, Fitzsimmons S C, Cahill B C, Hibbs J R, Marshall B C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153 345-352
63 Ordonez C L, Henig N R, Mayer-Hamblett N et al.. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168 1471-1475
64 Dakin C J, Numa A H, Wang H, Morton J R, Vertzyas C C, Henry R L. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002; 165 904-910
65 Paul K, Rietschel E, Ballmann M et al.. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004; 169 719-725
66 Birrer P, McElvaney N G, Rudeberg A et al.. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994; 150 207-213
67 Ratjen F, Hartog C M, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax. 2002; 57 930-934
68 Brown R K, Kelly F J. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax. 1994; 49 738-742
69 McGrath L T, Mallon P, Dowey L et al.. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax. 1999; 54 518-523
70 Hays S R, Ferrando R E, Carter R, Wong H H, Woodruff P G. Structural changes to airway smooth muscle in cystic fibrosis. Thorax. 2005; 60 226-228
71 Auerbach H S, Williams M, Kirkpatrick J A, Colten H R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985; 2 686-688
72 Eigen H, Rosenstein B J, FitzSimmons S, Schidlow D V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995; 126 515-523
73 Lai H C, FitzSimmons S C, Allen D B et al.. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000; 342 851-859
74 Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews (online). 2000 (2) CD001915
75 Balfour-Lynn I M, Lees B, Hall P et al.. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006; 173 1356-1362
76 Konstan M W, Byard P J, Hoppel C L, Davis P B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332 848-854
77 Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev. 1999; (2) , CD001505
78 Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006; 61 895-902
79 Equi A, Balfour-Lynn I M, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002; 360 978-984
80 Saiman L, Marshall B C, Mayer-Hamblett N et al.. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290 1749-1756
81 Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002; 57 212-216
82 Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med. 2004; 10 515-523
83 Cigana C, Nicolis E, Pasetto M, Assael B M, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006; 350 977-982
84 Schmitt-Grohe S, Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects. Paediatr Drugs. 2005; 7 353-363
85 Konstan M W, Doring G, Lands L et al,. on behalf of the investigators and coordinators of BI Trial 543.45. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Paediatric Pulmonol. 2005; 125-126
86 McElvaney N G, Hubbard R C, Birrer P et al.. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991; 337 392-394
87 Martin S L, Downey D, Bilton D, Keogan M T, Edgar J, Elborn J S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006; 41 177-183
88 Yarden J, Radojkovic D, De Boeck K et al.. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax. 2005; 60 320-325
89 Hothersall E, McSharry C, Thomson N C. Potential therapeutic role for statins in respiratory disease. Thorax. 2006; 61 729-734
90 Fessler M B, Young S K, Jeyaseelan S et al.. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med. 2005; 171 606-615
91 Kreiselmeier N E, Kraynack N C, Corey D A, Kelley T J. Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells. Am J Physiol. 2003; 285 L1286-L1295
92 Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006; 174 208-212
93 Ballmann M, Junge S, von der Hardt H. Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. Respir Med. 2003; 97 498-500

Duncan GeddesM.D. F.R.C.P.

Department of Respiratory Medicine, Royal Brompton Hospital

Sydney St., London SW3 6NP, UK

eMail: d.geddes@rbht.nhs.uk